These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35822611)

  • 1. Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow.
    Middleton AM; Reynolds J; Cable S; Baltazar MT; Li H; Bevan S; Carmichael PL; Dent MP; Hatherell S; Houghton J; Kukic P; Liddell M; Malcomber S; Nicol B; Park B; Patel H; Scott S; Sparham C; Walker P; White A
    Toxicol Sci; 2022 Aug; 189(1):124-147. PubMed ID: 35822611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of physiologically based kinetic (PBK) modelling in the next generation risk assessment of dermally applied consumer products.
    Moxon TE; Li H; Lee MY; Piechota P; Nicol B; Pickles J; Pendlington R; Sorrell I; Baltazar MT
    Toxicol In Vitro; 2020 Mar; 63():104746. PubMed ID: 31837441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products.
    Baltazar MT; Cable S; Carmichael PL; Cubberley R; Cull T; Delagrange M; Dent MP; Hatherell S; Houghton J; Kukic P; Li H; Lee MY; Malcomber S; Middleton AM; Moxon TE; Nathanail AV; Nicol B; Pendlington R; Reynolds G; Reynolds J; White A; Westmoreland C
    Toxicol Sci; 2020 Jul; 176(1):236-252. PubMed ID: 32275751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next-Generation Risk Assessment.
    Hatherell S; Baltazar MT; Reynolds J; Carmichael PL; Dent M; Li H; Ryder S; White A; Walker P; Middleton AM
    Toxicol Sci; 2020 Jul; 176(1):11-33. PubMed ID: 32374857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine.
    Bury D; Alexander-White C; Clewell HJ; Cronin M; Desprez B; Detroyer A; Efremenko A; Firman J; Hack E; Hewitt NJ; Kenna G; Klaric M; Lester C; Mahony C; Ouedraogo G; Paini A; Schepky A;
    Regul Toxicol Pharmacol; 2021 Jul; 123():104931. PubMed ID: 33905778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PBK modelling of topical application and characterisation of the uncertainty of C
    Li H; Reynolds J; Sorrell I; Sheffield D; Pendlington R; Cubberley R; Nicol B
    Toxicol Appl Pharmacol; 2022 May; 442():115992. PubMed ID: 35346730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients.
    Gilmour N; Kern PS; Alépée N; Boislève F; Bury D; Clouet E; Hirota M; Hoffmann S; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Osmani A; Petersohn D; Sekine S; van Vliet E; Klaric M
    Regul Toxicol Pharmacol; 2020 Oct; 116():104721. PubMed ID: 32645429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation risk assessment for skin allergy: Decision making using new approach methodologies.
    Gilmour N; Reynolds J; Przybylak K; Aleksic M; Aptula N; Baltazar MT; Cubberley R; Rajagopal R; Reynolds G; Spriggs S; Thorpe C; Windebank S; Maxwell G
    Regul Toxicol Pharmacol; 2022 Jun; 131():105159. PubMed ID: 35311660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
    Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
    Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hypothetical skin sensitisation next generation risk assessment for coumarin in cosmetic products.
    Reynolds G; Reynolds J; Gilmour N; Cubberley R; Spriggs S; Aptula A; Przybylak K; Windebank S; Maxwell G; Baltazar MT
    Regul Toxicol Pharmacol; 2021 Dec; 127():105075. PubMed ID: 34728330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategy for systemic toxicity assessment based on non-animal approaches: The Cosmetics Europe Long Range Science Strategy programme.
    Desprez B; Dent M; Keller D; Klaric M; Ouédraogo G; Cubberley R; Duplan H; Eilstein J; Ellison C; Grégoire S; Hewitt NJ; Jacques-Jamin C; Lange D; Roe A; Rothe H; Blaauboer BJ; Schepky A; Mahony C
    Toxicol In Vitro; 2018 Aug; 50():137-146. PubMed ID: 29499337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment.
    Alexander-White C; Bury D; Cronin M; Dent M; Hack E; Hewitt NJ; Kenna G; Naciff J; Ouedraogo G; Schepky A; Mahony C; Europe C
    Regul Toxicol Pharmacol; 2022 Mar; 129():105094. PubMed ID: 34990780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Read-across and new approach methodologies applied in a 10-step framework for cosmetics safety assessment - A case study with parabens.
    Ouedraogo G; Alexander-White C; Bury D; Clewell HJ; Cronin M; Cull T; Dent M; Desprez B; Detroyer A; Ellison C; Giammanco S; Hack E; Hewitt NJ; Kenna G; Klaric M; Kreiling R; Lester C; Mahony C; Mombelli E; Naciff J; O'Brien J; Schepky A; Tozer S; van der Burg B; van Vugt-Lussenburg B; Stuard S; Cosmetics Europe
    Regul Toxicol Pharmacol; 2022 Jul; 132():105161. PubMed ID: 35508214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling 58 compounds including cosmetic-relevant chemicals using ToxRefDB and ToxCast.
    Pham LL; Truong L; Ouedraogo G; Loisel-Joubert S; Martin MT; Paul Friedman K
    Food Chem Toxicol; 2019 Oct; 132():110718. PubMed ID: 31356915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods.
    Berggren E; White A; Ouedraogo G; Paini A; Richarz AN; Bois FY; Exner T; Leite S; Grunsven LAV; Worth A; Mahony C
    Comput Toxicol; 2017 Nov; 4():31-44. PubMed ID: 29214231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety assessment of personal care products/cosmetics and their ingredients.
    Nohynek GJ; Antignac E; Re T; Toutain H
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):239-59. PubMed ID: 20005888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients.
    Dent MP; Vaillancourt E; Thomas RS; Carmichael PL; Ouedraogo G; Kojima H; Barroso J; Ansell J; Barton-Maclaren TS; Bennekou SH; Boekelheide K; Ezendam J; Field J; Fitzpatrick S; Hatao M; Kreiling R; Lorencini M; Mahony C; Montemayor B; Mazaro-Costa R; Oliveira J; Rogiers V; Smegal D; Taalman R; Tokura Y; Verma R; Willett C; Yang C
    Regul Toxicol Pharmacol; 2021 Oct; 125():105026. PubMed ID: 34389358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision making in next generation risk assessment for skin allergy: Using historical clinical experience to benchmark risk.
    Reynolds J; Gilmour N; Baltazar MT; Reynolds G; Windebank S; Maxwell G
    Regul Toxicol Pharmacol; 2022 Oct; 134():105219. PubMed ID: 35835397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current opinion on risk assessment of cosmetics.
    Kim KB; Kwack SJ; Lee JY; Kacew S; Lee BM
    J Toxicol Environ Health B Crit Rev; 2021 May; 24(4):137-161. PubMed ID: 33832410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization.
    Paul Friedman K; Gagne M; Loo LH; Karamertzanis P; Netzeva T; Sobanski T; Franzosa JA; Richard AM; Lougee RR; Gissi A; Lee JJ; Angrish M; Dorne JL; Foster S; Raffaele K; Bahadori T; Gwinn MR; Lambert J; Whelan M; Rasenberg M; Barton-Maclaren T; Thomas RS
    Toxicol Sci; 2020 Jan; 173(1):202-225. PubMed ID: 31532525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.